Information  X 
Enter a valid email address

Sensyne Health PLC (SENS)

  Print   

Wednesday 26 January, 2022

Sensyne Health PLC

Publication of Circular, Notice of General Meeting

RNS Number : 7676Z
Sensyne Health PLC
26 January 2022
 

 

 

Sensyne Health plc


("Sensyne" or the "Company")

 

Publication of Circular and Notice of General Meeting

 

 

Oxford, U.K. -26 January 2022: Sensyne Health plc (LSE:SENS), the UK clinical AI company, announces that further to the announcement at 7.00 a.m. today of the successful completion of the Financing, a Circular has been published on the Company's website, www.sensynehealth.com, and will be posted to Shareholders today. The Circular contains the notice convening the General Meeting to be held at 2.00 p.m. on 11 February 2022.

 

The Board takes the health, safety, and wellbeing of all of the Company's stakeholders very seriously and Shareholders should note that as a result of the COVID-19 pandemic and the guidance published by the UK Government, physical attendance at the General Meeting may not be possible at the time of the meeting. In addition, and in accordance with the Articles, the Company may impose entry restrictions on attendance at the General Meeting. In light of this, the Board encourages Shareholders to submit their votes by proxy in advance by the required deadline of 2.00 p.m. on 9 February 2022 and to appoint the Chairman of the meeting as their proxy, with voting instructions, to ensure their vote is counted. If the Company intends to restrict physical attendance at the General Meeting, the Company will notify Shareholders of this, or any other change to the proposed format of the General Meeting, as soon as possible via RNS and its website at www.sensynehealth.com.

 

Unless otherwise indicated, capitalised terms in this announcement have the meaning given to them in the definitions section included in Appendix I of the announcement made at 7.00 a.m. today via RNS.

 

-ENDS-

 



Contact details:

Sensyne Health


 

Dr Richard Pye, Chief Financial Officer

 

+44 (0) 330 058 1845

 

Peel Hunt LLP (Nominated Adviser and Joint Broker)

+ 44 (0) 20 7418 8900

 

Dr Christopher Golden

James Steel

 


 

Liberum (Joint Broker)


Bidhi Bhoma

Phil Walker

William Hall

+ 44 (0) 20 3100 2000

Consilium Strategic Communications


Mary-Jane Elliott

Jessica Hodgson

[email protected]

+44 (0) 7780 600290

SternIR


Julie Seidel

[email protected]

  +1 (212) 362 1200



Notes for editors:

About Sensyne Health : https://www.sensynehealth.com/

Sensyne Health plc (LSE: SENS) is a clinical artificial intelligence company operating a unique business model - a for-profit plc making a positive social impact, sharing the financial returns it makes with health systems.  The company applies clinical AI in the healthcare and life science industries. In healthcare, Sensyne delivers remote patient monitoring and real-time decision-making systems for healthcare organisations and their patients. In life sciences, Sensyne analyses large complex anonymized data sets to help life sciences companies accelerate the development of new medicines.

Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FURPPUWPGUPPGRQ

a d v e r t i s e m e n t